Unlocking Hope: ACE Inhibitors Show Powerful Potential in Reducing Mortality for Idiopathic Pulmonary Fibrosis Patients

A recent study published in the Chest Journal reveals that angiotensin-converting enzyme (ACE) inhibitors may play a significant role in decreasing all-cause mortality among patients with idiopathic pulmonary fibrosis (IPF). This revelation has sparked interest in repurposing ACE inhibitors, a class of medications traditionally used to treat conditions like hypertension and congestive heart failure-ailments that frequently co-exist with IPF, which often affects individuals over 50 years old, particularly men. The median survival rate for patients diagnosed with IPF typically ranges from three to five years, making effective treatment strategies critical.

Research conducted with patient-level electronic health records from the Clinical Practice Research Data (CPRD) GP Online Database included individuals diagnosed with IPF between January 2002 and January 2019, aged between 40 and 85 years. The analysis aimed to compare mortality rates in IPF patients treated with ACE inhibitors against those suffering from chronic obstructive pulmonary disease (COPD), another chronic respiratory condition with overlapping comorbidities. The study involved a sample of 3,579 IPF patients matched 1:1 with an equal number of COPD patients for robust comparison.

Of the IPF cohort, 1,328 were treated with ACE inhibitors. Among them, 1,117 deaths were documented (86%) compared to 1,900 deaths (84%) in those not using the medication. In a Cox regression analysis, ACE inhibitors showed a significant association with improved survival rates (HR, 0.99; 95% CI, 0.92-1.06; P = .72). More importantly, a multivariable Cox regression analysis adjusted for confounding factors indicated an independent association between ACE inhibitor use and reduced mortality (HR, 0.82; 95% CI, 0.75-0.91; P < .0001).

Interestingly, the causes of death among ACE inhibitor users predominantly included respiratory complications (45%) and cardiovascular issues (18%). In contrast, the non-user group saw higher rates of respiratory-related deaths (48%) but lower cardiovascular fatalities (11%). However, when adjusted for all potential causes of death, ACE inhibitors did not significantly correlate with a reduction in respiratory-related mortality.

When the ACE inhibitor group in the IPF cohort was compared to the COPD group, where 717 deaths (20%) occurred in users versus 1,692 (47%) in non-users, no significant influence on mortality was established (HR, 1.09; 95% CI, 0.96-1.23; P = .180).

The retrospective nature of the study presents limitations regarding causal inference, and potential confounding factors might remain, despite using propensity score matching. Additionally, IPF diagnoses were derived from electronic health records, raising concerns of possible coding inaccuracies. Nonetheless, the authors note that the resultant survival rates suggest the impact of these discrepancies is minimal.

As the researchers concluded, “These findings highlight the value of investigating well-established medications for new therapeutic roles in progressive diseases such as IPF, where current treatment options remain limited.” They advocate for prospective trials to confirm these findings and further delve into the therapeutic potential of ACE inhibitors for patients battling IPF.

This study opens new avenues for treatment in IPF, emphasizing the need for continued exploration of existing medications to address the pressing challenges faced by patients.

Tags: ACE inhibitors, idiopathic pulmonary fibrosis, COPD, all-cause mortality, clinical research, respiratory diseases

Original Source: https://www.ajmc.com/view/ace-inhibitors-linked-to-reduced-mortality-in-patients-with-idiopathic-pulmonary-fibrosis
Category :
Tags:
Publish Date: 2026-01-27 03:30:00